A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials.
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 06 Oct 2017 Planned number of patients changed from 450 to 340.
- 14 Mar 2016 Planned End Date changed from 1 Apr 2023 to 1 Mar 2023, according to ClinicalTrials.gov record.
- 14 Mar 2016 Planned primary completion date changed from 1 Apr 2023 to 1 Mar 2023, according to ClinicalTrials.gov record.